CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer

[1]  Wenchuan Wu,et al.  Neutralizing TGF-β promotes anti-tumor immunity of dendritic cells against pancreatic cancer by regulating T lymphocytes , 2018, Central-European journal of immunology.

[2]  Lianfang Zheng,et al.  PD-1/PD-L1 and immunotherapy for pancreatic cancer. , 2017, Cancer letters.

[3]  Manish B. Patel,et al.  Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX , 2017, Expert review of clinical pharmacology.

[4]  K. Hirakawa,et al.  The Prognostic Significance of the Tumor-infiltrating Programmed Cell Death-1+ to CD8+ Lymphocyte Ratio in Patients with Colorectal Cancer. , 2017, Anticancer research.

[5]  D. Busch,et al.  Cytomegalovirus vector expressing RAE‐1γ induces enhanced anti‐tumor capacity of murine CD8+ T cells , 2017, European journal of immunology.

[6]  A. Zaniboni,et al.  Immunotherapy for pancreatic cancer: present and future. , 2017, Immunotherapy.

[7]  X. Bai,et al.  [Advances in immunotherapy of pancreatic ductal adenocarcinoma]. , 2017, Zhonghua wai ke za zhi [Chinese journal of surgery].

[8]  Nicolai J. Birkbak,et al.  Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors , 2017, Immunity.

[9]  E. Munck‐Wikland,et al.  Validation of Human Papillomavirus as a Favourable Prognostic Marker and Analysis of CD8+ Tumour-infiltrating Lymphocytes and Other Biomarkers in Cancer of Unknown Primary in the Head and Neck Region. , 2017, Anticancer research.

[10]  Z. Ahmad,et al.  Building a better understanding of the burden of disease in familial chylomicronemia syndrome , 2017, Expert review of clinical pharmacology.

[11]  R. Xu,et al.  The TGF-β/Smad4 Signaling Pathway in Pancreatic Carcinogenesis and Its Clinical Significance , 2017, Journal of clinical medicine.

[12]  Yufeng Zou,et al.  Interleukin-12 activated CD8+ T cells induces apoptosis in breast cancer cells and reduces tumor growth. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[13]  Xuefang Li,et al.  A mathematical prognosis model for pancreatic cancer patients receiving immunotherapy. , 2016, Journal of theoretical biology.

[14]  D. Sandnes,et al.  The TGFβ-SMAD3 pathway inhibits IL-1α induced interactions between human pancreatic stellate cells and pancreatic carcinoma cells and restricts cancer cell migration , 2016, Journal of experimental & clinical cancer research : CR.

[15]  J. Taube,et al.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.

[16]  E. Jaffee,et al.  TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner , 2015, Oncotarget.

[17]  C. Drake,et al.  Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.

[18]  Lixin Wei,et al.  TGF-β Regulates Hepatocellular Carcinoma Progression by Inducing Treg Cell Polarization , 2015, Cellular Physiology and Biochemistry.

[19]  S. Leung,et al.  Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration , 2014, Breast Cancer Research.

[20]  Donghui Li,et al.  Biomarkers of TGF-β Signaling Pathway and Prognosis of Pancreatic Cancer , 2014, PloS one.

[21]  E. Raymond,et al.  Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas , 2013, Oncotarget.

[22]  Hongtao Zhang,et al.  Lysosome-dependent p300/FOXP3 degradation and limits Treg cell functions and enhances targeted therapy against cancers. , 2013, Experimental and molecular pathology.

[23]  J. Ahn,et al.  Prognostic impact of FOXP3 expression in triple-negative breast cancer , 2013, Acta oncologica.

[24]  A. DeMichele,et al.  CD25 Blockade Depletes and Selectively Reprograms Regulatory T Cells in Concert with Immunotherapy in Cancer Patients , 2012, Science Translational Medicine.

[25]  R. deLeeuw,et al.  The Prognostic Value of FoxP3+ Tumor-Infiltrating Lymphocytes in Cancer: A Critical Review of the Literature , 2012, Clinical Cancer Research.

[26]  R. McLendon,et al.  Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans. , 2011, Blood.

[27]  E. Ranieri,et al.  TGF-β promotes immune suppression by inhibiting Treg cell apoptosis. , 2010, Immunotherapy.

[28]  E. Ranieri,et al.  Role of cytotoxic CD4+ T cells in cancer immunotherapy. , 2010, Immunotherapy.

[29]  Kohei Miyazono,et al.  TGFβ signalling: a complex web in cancer progression , 2010, Nature Reviews Cancer.

[30]  K. Ohkusu-Tsukada,et al.  Targeted inhibition of IL‐10‐secreting CD25− Treg via p38 MAPK suppression in cancer immunotherapy , 2010, European journal of immunology.

[31]  Y. Setiady,et al.  In vivo depletion of CD4+FOXP3+ Treg cells by the PC61 anti‐CD25 monoclonal antibody is mediated by FcγRIII+ phagocytes , 2010, European journal of immunology.

[32]  J. Barkun,et al.  Long-term immunosuppression with anti-CD25 monoclonal antibodies in heart transplant patients with chronic kidney disease. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[33]  M. Toda,et al.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.

[34]  Wenchuan Wu,et al.  Survival prediction in pancreatic cancer patients with no distant metastasis: a large-scale population-based estimate. , 2018, Future Oncology.

[35]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[36]  Wenchuan Wu,et al.  Low intratumoral regulatory T cells and high peritumoral CD8+ T cells relate to long-term survival in patients with pancreatic ductal adenocarcinoma after pancreatectomy , 2015, Cancer Immunology, Immunotherapy.